Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Genedrive revenues rise as it waits for EU approval

Genedrive’s HCV assay provides on-the-spot results in just 90 minutes direct from a very small plasma sample.
picture of Genedrive device
Test results come back within 90 minutes

Genedrive PLC (LON:GDR) boosted revenues by 45% in its latest half year as it prepares for the launch of its hepatitis C test once it gets an award of CE mark.

The receipt of CE IVD certification under the EU Medical Devices Directive would green-light the commercialisation of the product in the European Union.

Genedrive’s HCV assay provides on-the-spot results in just 90 minutes direct from a very small plasma sample.

Revenues in the half year to December rose to £2.9mln (£2mln), with sales related to Genedrive up 71% to £1.2mln.

Investment in the hand-held device, however, meant losses of £2.7mln in the year. The company had cash at the period-end of £5.7mln.

David Budd, Genedrive’s chief executive, said: "The recent period has seen genedrive plc continue to focus on the significant opportunity we see in molecular diagnostics with our rapid, point of need Genedrive system.

“In Hepatitis C, we are making very positive progress. Our recent application for CE certification positions us well to be first to market with a decentralised point of need HCV qualitative test which would enable real-time treatment and management of chronic HCV patients with the new generation of direct acting antivirals. 

"Despite the difficulties in accessing the full potential of the Genedrive system thus far through the MTB/RIF launch, the Board remains confident of the business strategy. “

PhilW.jpg
Why Invest In Genedrive PLC? Read More Here

Register here to be notified of future GDR Company articles
View full GDR profile View Profile

Genedrive PLC Timeline

Related Articles

Knee surgery
February 02 2017
The treatment involves removing cellular material from animal and human tissue to leave a matrix which gives a framework for population by the patient’s own cells.
Lab.jpg
April 05 2017
The share placing follows a period of expansion that has seen it make two major acquisition
cancer cells
January 24 2017
The US-based, London-listed healthcare group topped expectations with its latest results and analysts are tipping it for more success this year

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use